Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44173   clinical trials with a EudraCT protocol, of which   7329   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-004566-17
    Sponsor's Protocol Code Number:EORTC-1820-CLTF
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-05-25
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2019-004566-17
    A.3Full title of the trial
    Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma
    Étude de phase II, multicentrique menée en ouvert, portant sur l’anticorps monoclonal anti-CCR4 (mogamulizumab) et l’irradiation totale de la peau par électronthérapie (Total Skin Electron Beam, TSEB) chez des patients ayant un lymphome T cutané de stade IB-IIB (MOGAT)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase II study of a monoclonal antibody, mogamulizumab, associated with radiotherapy called total skin electron beam (TSEB), in patients with cutaneous T-cell lymphoma
    Étude de phase II d’un anticorps monoclonal, le mogamulizumab, associé à la radiothérapie,irradiation totale de la peau par électronthérapie (TSEB), chez des patients ayant un lymphome T cutané
    A.3.2Name or abbreviated title of the trial where available
    MOGAT
    A.4.1Sponsor's protocol code numberEORTC-1820-CLTF
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04128072
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorEuropean Organisation for Research and Treatment of Cancer
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportEuropean Organisation for the Research and Treatment of Cancer
    B.4.2CountryBelgium
    B.4.1Name of organisation providing supportKyowa Kirin
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationEuropean Organisation for the Research and Treatment of Cancer
    B.5.2Functional name of contact pointRegulatory Affairs Department
    B.5.3 Address:
    B.5.3.1Street Address83/11 Avenue E. Mounier
    B.5.3.2Town/ cityBrussels
    B.5.3.3Post code1200
    B.5.3.4CountryBelgium
    B.5.4Telephone number+322774 10 35
    B.5.5Fax number+322772 70 63
    B.5.6E-mailregulatory@eortc.org
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name POTELIGEO
    D.2.1.1.2Name of the Marketing Authorisation holderKyowa Kirin Holdings B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/16/1756
    D.3 Description of the IMP
    D.3.1Product nameKW-0761 (Mogamulizumab)
    D.3.2Product code KW-0761
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMogamulizumab
    D.3.9.1CAS number 1159266-37-1
    D.3.9.2Current sponsor codeKW-0761
    D.3.9.3Other descriptive nameMOGAMULIZUMAB
    D.3.9.4EV Substance CodeSUB85518
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Cutaneous T-cell lymphoma (Mycosis Fungoides (MF) and Sézary Syndrome (SS))
    Le lymphome T cutané (le mycosis fongoïde) et le syndrome de Sézary
    E.1.1.1Medical condition in easily understood language
    Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin
    Le mycosis fongoïde est un cancer dans lequel les lymphocytes (un type de cellules immunitaires) deviennent cancéreux et affectent la peau.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level LLT
    E.1.2Classification code 10028502
    E.1.2Term Mycosis fungoides refractory
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level LLT
    E.1.2Classification code 10028504
    E.1.2Term Mycosis fungoides stage II
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level LLT
    E.1.2Classification code 10028503
    E.1.2Term Mycosis fungoides stage I
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level LLT
    E.1.2Classification code 10028508
    E.1.2Term Mycosis fungoides/Sezary syndrome
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level LLT
    E.1.2Classification code 10028511
    E.1.2Term Mycosis fungoides/Sezary syndrome refractory
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level LLT
    E.1.2Classification code 10028512
    E.1.2Term Mycosis fungoides/Sezary syndrome stage I
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level LLT
    E.1.2Classification code 10028513
    E.1.2Term Mycosis fungoides/Sezary syndrome stage II
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLGT
    E.1.2Classification code 10025321
    E.1.2Term Lymphomas non-Hodgkin's T-cell
    E.1.2System Organ Class 10005329 - Blood and lymphatic system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the progression free survival rate at 48 weeks (according to EORTC-ISCL-USCLC criteria) of anti-CCR4 monoclonal antibody (mogamulizumab) and TSEB in IB-IIB cutaneous T-cell lymphoma.
    D’évaluer le taux de survie sans progression à 48 semaines (selon les critères EORTC-ISCLUSCLC) de l’anticorps monoclonal anti-CCR4 (mogamulizumab) et de la TSEB dans le lymphome T cutané de stade IB-IIB.
    E.2.2Secondary objectives of the trial
    • To evaluate the overall safety
    • To assess the response rate
    • To assess the progression-free survival
    • To assess the overall survival
    • To assess the time to progression
    • To evaluate the duration of response
    • To evaluate the time to next significant treatment
    - Évaluer l’innocuité globale
    - Évaluer le taux de réponse
    - Évaluer la survie sans progression
    - Évaluer la survie globale
    - Évaluer le délai avant la progression
    - Évaluer la durée de réponse
    - Évaluer le délai avant le prochain traitement significatif
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Males and female subjects ≥ 18 years;
    • Mycosis fungoides stage IB, IIA, IIB;
    • Subjects who have failed at least one prior course of systemic therapy. Psoralen plus ultraviolet light therapy (PUVA) is not considered to be a systemic therapy;
    • Adequate haematological and organ function;
    • Signed informed consent
    - Patients hommes et femmes ≥ 18 ans
    - Ayant un mycosis fongoïde de phase IB, IIA, IIB
    - Patients ayant échappé à au moins une ligne antérieure de traitement systémique. La PUVAthérapie (PUVA) n'est pas considérée comme une thérapie systémique
    - Absence de comorbidités significatives
    - Consentement éclairé signé
    E.4Principal exclusion criteria
    • Prior treatment with mogamulizumab;
    • Prior TSEB;
    • Known hypersensitivity to CHO cell products or any component of the mogamulizumab formulation;
    • Significant uncontrolled intercurrent illness
    - Traitement antérieur par mogamulizumab
    - Traitement antérieur par TSEB
    - Hypersensibilité connue aux produits cellulaires CHO ou à tout composant de la formulation de mogamulizumab;
    - Maladie intercurrente incontrôlée importante
    E.5 End points
    E.5.1Primary end point(s)
    Progression Free Survival Rate at 48 weeks (PFSR-48)
    Taux de survie sans progression à 48 semaines (TSSP-48)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Up to 48 weeks after start of mogamulizumab for each patient
    Jusqu’à 48 semaines après le début du mogamulizumab pour chaque patient
    E.5.2Secondary end point(s)
    • Overall safety of both mogamulizumab and TSEB;
    • Response rate (RR) to both mogamulizumab and TSEB ;
    • Progression-free survival (PFS) ;
    • Overall survival (OS);
    • Time to progression ;
    • Duration of response ;
    • Time to next treatment.

    Exploratory endpoints:
    Quality of life: Skindex-29 and EORTC-QLQ-C30, and time to treatment failure.
    - Innocuité globale du mogamulizumab et de la TSEB
    - Taux de réponse au mogamulizumab et à la TSEB
    - Survie sans progression
    - Survie globale
    - Délai jusqu’à la progression
    - Durée de réponse
    - Délai jusqu’au prochain traitement

    Critères d’évaluation exploratoires :
    Qualité de vie : Skindex-29 et EORTC-QLQ-C30 et temps jusqu’à l’échec du traitement.
    E.5.2.1Timepoint(s) of evaluation of this end point
    • Overall safety: 48 months after last patient in;
    • RR: from the first patient treatment start till 48 weeks as of last patient in;
    • PFS: from the first patient treatment start till 48 weeks as of last patient in;
    • OS: from the first patient treatment start till 5 years after last patient treatment;
    • Time to progression: from the first patient treatment start till 48 weeks as of last patient in;
    • Duration of resp: from the first patient treatment start till 48 weeks as of last patient in;
    • Time to next treatment: from the first patient treatment start till 48 weeks as of last patient in.
    Innocuité globale du moga et de la TSEB: 48 mois après l’inclusion du dernier patient
    Taux de réponse au moga et à la TSEB et survie sans progression : dès le début du traitement du premier patient jusqu’à 48 semaines après l’inclusion du dernier patient
    Survie globale: dès le début du traitement du premier patient jusqu’à 5 ans après le dernier traitement du dernier patient
    Délai jusqu’à la progression: dès le début du traitement du premier patient jusqu’à 48 semaines après l’inclusion du dernier patient
    Durée de réponse: dès le début du traitement du premier patient jusqu’à 48 semaines après l’inclusion du dernier patient
    Délai jusqu’au prochain traitement: dès le début du traitement du premier patient jusqu’à 48 semaines après l’inclusion du dernier patient
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Radiotherapy, Biobanking, Quality of Life
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA13
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Finland
    France
    Germany
    Greece
    Italy
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of study occurs when all of the following criteria have been satisfied:
    1. Ninety days after all patients have stopped protocol treatment
    2. The trial is mature for the analysis of the primary endpoint as defined in the protocol
    3. The database has been fully cleaned and frozen for this analysis
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 21
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 22
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state5
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 38
    F.4.2.2In the whole clinical trial 43
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After progression, the treatment will be left to the discretion of the treating physician
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-07-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-07-22
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA